Xinjian Zhu

Prof. Xinjian Zhu

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2017 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
XZXinjian Zhu
Xinjian Zhu
JDJingde Dong
Jingde Dong
BHBing Han
Bing Han
RHRongrong Huang
Rongrong Huang
AZAifeng Zhang
Aifeng Zhang
HYHonghong Yao
Honghong Yao
Epilepsy is one of the most common chronic neurological disorders which provoke progressive neuronal degeneration. Endoplasmic reticulum (ER) stress has recently been recognized as pivotal etiological factors contributing to epilepsy-induced neuronal damage. However, the specific contribution of epilepsy made to ER stress remains largely elusive. Here we use pentylenetetrazole (PTZ) kindling, a chronic epilepsy model, to identify neuronal nitric oxide synthase (nNOS) as a signaling molecule triggering PTZ kindling epilepsy-induced ER stress and oxidative damage. By genetic deletion of nNOS gene, we further demonstrated that nNOS acts through peroxynitrite, an important member of reactive nitrogen species, to trigger hippocampal ER stress and oxidative damage in the PTZ-kindled mice. Our findings thus define a specific mechanism for chronic epilepsy-induced ER stress and oxidative damage, and identify a potential therapeutic target for neuroprotection in chronic epilepsy patients.

1 May 2015 in Brain Research Bulletin
Verified
Journal Article
Closed access
XZXinjian Zhu
Xinjian Zhu
JDJingde Dong
Jingde Dong
KSKai Shen
Kai Shen
YBYing Bai
Ying Bai
YZYuan Zhang
Yuan Zhang
HYHonghong Yao
Honghong Yao

17 February 2015 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
YZYuan Zhang
Yuan Zhang
XLXuan Lv
Xuan Lv
YBYing Bai
Ying Bai
XZXinjian Zhu
Xinjian Zhu
XWXiaodong Wu
Xiaodong Wu
HYHonghong Yao
Honghong Yao
Although it has been documented that methamphetamine induces astrocyte activation, the mechanism(s) underlying this effect remain poorly understood. We thus sought to examine the molecular mechanisms involved in methamphetamine-mediated activation of astrocytes with a focus on the role of sigma-1 receptor (σ-1R) in this process. The expression of σ-1R and glial fibrillary acidic protein (GFAP) was examined by reverse transcription PCR (RT-PCR), real-time PCR, Western blot, and immunofluorescent staining; phosphorylation of cell signaling pathways was detected by Western blot analysis. Immunoprecipitation was used to determine the interaction between σ-1R and p-Src. Chromatin immunoprecipitation (ChIP) assay was employed to discern the binding of cAMP-response element-binding protein (CREB) with the promoter of σ-1R. The role of σ-1R in astrocyte activation was further validated in σ-1R knockout (KO) mice by Western blot combined with immunofluorescent staining. Exposure of primary rat astrocytes to methamphetamine increased the expression of σ-1R via the activation of Src, ERK mitogen-activated protein kinase, and downstream CREB pathways. Subsequently, CREB translocated into nucleus and interacted with the promoter of σ-1R resulting in increased expression of σ-1R with a concomitant increase in expression of GFAP. This effect was inhibited in cells treated with the σ-1R antagonist-BD1047, thereby implicating the role of σ-1R in the activation of astrocytes. In vivo relevance of these findings was further corroborated in σ-1R KO mice that were administered methamphetamine. In the methamphetamine administered mice, there was a failure of the drug to induce activation of astrocytes, an effect that was evident in wild-type (WT) mice exposed to methamphetamine. The study presented herein demonstrates that methamphetamine-mediated activation of astrocytes involved up-regulation of σ-1R through a positive-feedback mechanism. Understanding the regulation of σ-1R expression could provide insights into the development of potential therapeutic strategies for astrocyte activation induced by methamphetamine.

1 May 2016 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
XZXinjian Zhu
Xinjian Zhu
KSKai Shen
Kai Shen
YBYing Bai
Ying Bai
AZAifeng Zhang
Aifeng Zhang
ZXZhengrong Xia
Zhengrong Xia
HYHonghong Yao
Honghong Yao

1 October 2020 in International Immunopharmacology
Verified
Journal Article
Closed access
XZXinjian Zhu
Xinjian Zhu
YYYuanyuan Yao
Yuanyuan Yao
JYJiurong Yang
Jiurong Yang
JZJunhao Zhengxie
Junhao Zhengxie
XLXinyan Li
Xinyan Li
GGGuangming Gan
Guangming Gan

18 October 2017 in Frontiers in Behavioral Neuroscience
Verified
Journal Article
Open access
PDF file
XZXinjian Zhu
Xinjian Zhu
JDJingde Dong
Jingde Dong
BHBing Han
Bing Han
RHRongrong Huang
Rongrong Huang
AZAifeng Zhang
Aifeng Zhang
HYHonghong Yao
Honghong Yao
Epilepsy is a chronic neurological disease which is usually associated with psychiatric comorbidities. Depsression and cognition impairment are considered to be the most common psychiatric comorbidities in epilepsy patients. However, the specific contribution of epilepsy made to these psychiatric comorbidities remains largely unknown. Here we use pentylenetetrazole (PTZ) kindling, a chronic epilepsy model, to identify neuronal nitric oxide synthase (nNOS) as a signaling molecule triggering PTZ kindling-induced cognitive impairment and depressive-like behavior. Furthermore, we identified that both hippocampal MAPK and PI3K/AKT signaling pathways were activated in response to PTZ kindling, and the increased MAPK and PI3K/AKT signaling activation was paralleled by increased level of reactive oxygen species (ROS) in the hippocampus. However, the PTZ kindling-induced MAPK, PI3K/AKT signaling activities and the ROS level were attenuated by nNOS gene deficiency, suggesting that nNOS may act through ROS-mediated MAPK and PI3K/AKT signaling pathways to trigger cognition deficit and depressive-like behavior in PTZ-kindled mice. Our findings thus define a specific mechanism for chronic epilepsy-induced cognitive impairment and depressive-like behavior, and identify a potential therapeutic target for psychiatric comorbidities in chronic epilepsy patients.